SPACInsider Logo
Delwinds Insurance (DWIN) Announces Anticipated FPA and Revised Backstop
by Marlena Haddad on 2022-09-12 at 1:47pm

Delwinds Insurance (NYSE:DWIN) announced in a press release this afternoon that it will be entering into a forward purchase agreement with an institutional investor and its affiliates in connection to its proposed merger with FOXO Technologies.

As of the date of consummation of the business combination, the parties expect to purchase a certain number of shares of DWIN common stock and may purchase up to an additional 3 million shares from other holders. These shares would be subject to an agreement for up to fifteen months following the closing of the business combination. Additionally, the investor has the right to sell the shares in the open market, and at the end of the term of the agreement, or upon an accelerated maturity date.

Upon entering into this investor agreement, Delwinds expects its previous backstop agreement to be revised. The amendment is anticipated to reflect that the FPA is among the arrangements intended to reduce the backstop investors’ obligations under the agreements, as a result of which, upon the expected non-redemption of public shares in connection with the anticipated investor arrangement, the backstop investors would be not be obligated, and are not expected to, subscribe for DWIN shares.

Today’s FPA comes just two days before DWIN’s special meeting to vote on its business combination with FOXO.  Delwind is funding the deal with approximately $111 million cash from its current trust (down from $201 million after extension vote redemptions), and has not supplemented this with a PIPE.

FOXO’s recent capital raising transactions include a convertible debenture offering, led by institutional investors and joined by The Gray Insurance Company, which generated a minimum of $22.5 million of cash proceeds to FOXO prior to consummation of the transaction.

Although the deal does not include a minimum cash closing requirement, Andrew J. Poole, Chairman and CEO Delwinds, alongside Gray & Company, Inc. have committed to invest up to $10 million in the form of cash or debt in the event that the Delwinds trust does not maintain at least $10 million in cash following redemptions.

Additionally, FOXO secured a $40 million committed equity facility from CF Principal Investments LLC. Under the agreement, CF Principal Investments will provide a Facility of up to $40 million for 36 months following the date when the SEC has declared effective a registration statement covering the stock that will be included in the Facility or until the date on which the Facility has been fully utilized. FOXO will control the timing of each drawdown under the Facility and does not have a minimum drawdown obligation.

Delwinds announced its $369 million combination with FOXO Technologies earlier this year on February 24. Minneapolis, Minnesota-based FOXO Technologies utilizes AI-driven bioinformatics and technologies to develop and commercialize epigenetic biomarkers of health and aging.

 

 

Recent Posts
by Kristi Marvin on 2023-01-28 at 1:59pm

Terms Tracker for the Week Ending January 27, 2022 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re coming up on the end of January, the first month of the year, and to-date no new S-1s have been filed. Additionally, the number...

by Marlena Haddad on 2023-01-27 at 11:34am

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...

by Nicholas Alan Clayton on 2023-01-27 at 10:00am

Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change.  However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...

by Kristi Marvin on 2023-01-27 at 7:33am

Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...

by Nicholas Alan Clayton on 2023-01-27 at 7:30am

In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...

Privacy Policy|Terms Of Use
Copyright © 2022 SPACInsider, Inc. All Rights Reserved